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A double-blind randomized crossover trial of two loop diuretics
in chronic kidney disease.
Background. Torsemide has predictable absorption com-
pared to furosemide. Thereby, torsemide results in more con-
stant exposure to active drug. Our hypothesis was that this
pharmacokinetic difference between these commonly used
loop diuretics may translate into disparate antihypertensive
responses in patients with chronic kidney disease (CKD).
Methods. We conducted a randomized, double-blind, two-
period, crossover trial to compare the pharmacodynamics of
torsemide and furosemide, in 14 subjects with stage 2 or 3
CKD. We first performed an inpatient study, where after the
subjects were brought into sodium balance on a 200 mEq per
day diet, a single bioequivalent dose of oral loop diuretic was
administered with an intervening washout period. Measure-
ments of urinary electrolytes were made. Subjects then partici-
pated in an outpatient study, wherein they received daily ther-
apy for 3 weeks with the loop diuretics in random order. Twenty
four-hour ambulatory blood pressure monitoring was per-
formed before and after each drug to assess the antihyperten-
sive response.
Results. In the inpatient phase, furosemide increased urinary
sodium excretion from average (SD) 199  49 mEq/day to
357  96 mEq/day and torsemide increased urinary sodium
excretion from 213  79 mEq/day to 398  142 mEq/day.
These differences between the diuretics were not significant,
confirming bioequivalence. In the outpatient phase, furosemide
reduced 24-hour ambulatory blood pressure from 147 
17/78  11 mm Hg to 138  21/74  12 mm Hg (P  0.021)
and torsemide reduced it from 143  18/75  10 mm Hg to
133  19/71  10 mm Hg (P  0.007). Although each diuretic
was effective in reducing ambulatory blood pressure, the differ-
ences between diuretics were not statistically significant.
Conclusion. Bioequivalent doses of torsemide and furose-
mide given in a randomized, double-blind design fail to demon-
strate superiority of torsemide with respect to natriuresis or
24-hour ambulatory blood pressure control in subjects with
stages 2 and 3 CKD.
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Hypertension is a frequently observed disorder in pa-
tients with chronic kidney disease (CKD), ranging in prev-
alence from 60% to 100% [1]. The presence of hyperten-
sion places patients with kidney disease at risk of further
deterioration of kidney function, as well as cardiovas-
cular disease. As kidney function declines, retention of
sodium and water contributes to the pathophysiology of
hypertension. Accordingly, diuretics are valuable antihy-
pertensive agents in patients with CKD.
The loop diuretics torsemide and furosemide have dif-
ferent pharmacokinetic properties that may provide for
a difference in antihypertensive efficacy in patients with
CKD. Torsemide exhibits a bioavailability of 90% to
100% in both the presence and absence of CKD [2] and
is predominately cleared from the circulation by hepatic
metabolism. The large component of nonrenal clearance
results in an elimination half-life of torsemide that is
essentially unchanged in patients with CKD. The metab-
olites of torsemide do not contribute significantly to the
diuretic action of torsemide [2]. Conversely, the bioavail-
ability of furosemide in patients with normal kidney func-
tion is extremely variable, ranging between 11% and
90% [3]. The absorption of furosemide may be decreased
in CKD. Tilstone et al [4] found that in healthy control
subjects, the bioavailability of furosemide was 68.9%,
compared to 43.4% in subjects with severe CKD. More-
over, food decreases the absorption of furosemide but
does not affect torsemide [5, 6]. The elimination half-
life of furosemide is prolonged as kidney function de-
clines [4, 7].
The varying pharmacologic properties of torsemide
and furosemide, particularly when modified by the pres-
ence of impaired kidney function, may translate into a
clinically relevant difference in natriuretic response. In
turn, these discordant acute natriuretic responses may
elicit a difference in blood pressure reduction. However,
there are few comparative data on acute natriuretic and
chronic blood pressure lowering effects of these drugs
in patients with CKD [8–10]. Furthermore, these studies
provide conflicting results. We reasoned that torsemide
would produce better overall natriuresis than furosemide
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due to its superior and consistent bioavailability. This
natriuresis, in turn, would cause greater blood pressure
reduction in patients with CKD.
METHODS
Subjects
Study participants were recruited from the Nephrol-
ogy Clinic at the Richard L. Roudebush VA Medical
Center. Subjects were at least 18 years of age, had CKD
as determined by serum creatinine greater than 1.4 mg/dL,
and volume overload defined by hypertension (average
of three seated sitting cuff blood pressure130/80 mm Hg
or125/75 mm Hg if the subject had proteinuria greater
than 1 g/day) with or without edema. Subjects were ex-
cluded if the calculated glomerular filtration rate (GFR)
was less than 30 mL/min by the six-component Modified
Diet in Renal Disease (MDRD) formula [11], if they
were experiencing symptomatic congestive heart failure,
uncontrolled hypertension (blood pressure greater than
180/110 mm Hg), active nephritis, had experienced a cereb-
rovascular accident or myocardial infarction within 3
months, cirrhosis or chronic liver disease, gastroparesis,
titration of antihypertensive therapy within 1 month of
study participation, had an abnormal serum potassium
concentration, an allergy to radiocontrast dye, furosemide,
torsemide or sulfa drugs, were anticipated to require hemo-
dialysis within 3 months, or had concomitant use of chole-
styramine, probenecid, or high-dose aspirin. Usage of di-
uretics or nonsteroidal anti-inflammatory drugs 1 month
prior to study participation was prohibited.
The protocol was approved by the Institutional Re-
view Board at Indiana University School of Medicine
and the Richard L. Roudebush VA Medical Center.
Written informed consent was obtained from each sub-
ject prior to study participation.
Study design
The design was a randomized, fixed-dose, double-blind,
single-center, crossover trial involving an inpatient so-
dium balance study and an outpatient blood pressure
efficacy study. An allocation and randomization scheme
was generated by a biostatistician and concealed from
the investigators. This scheme was directly given to an
institutional investigational drug pharmacy, which masked
the furosemide (Roxane Laboratories, Columbus, OH,
USA) and torsemide (Roche, Indianapolis, IN, USA)
tablets by encapsulation in identical opaque gelcaps (size
00 white gelcaps, Gallipot, Inc., Eagan, MN, USA).
Inpatient sodium balance study. Inpatient trial design
is illustrated in Figure 1A. Subjects were admitted to the
General Clinical Research Center (GCRC) for 7 days for
the sodium balance study. From 3 days prior to admission
and until the completion of the sodium balance study,
subjects consumed a study diet prepared by the GCRC
Fig. 1. Study designs. (A ) Inpatient sodium balance study design. *De-
notes 24-hour urine collection for electrolytes and protein. Washout
period between study medications was 2 days in duration. Shaded bar
denotes administration of 200 mEq sodium-containing study diet. Wash-
out period between inpatient sodium balance and outpatient blood
pressure study phases was 1 week in duration. (B ) Outpatient blood
pressure efficacy study design. Washout period in between study medi-
cations was 2 weeks in duration. ABPM denotes ambulatory blood
pressure monitoring.
consisting of daily intake of 200 mEq sodium, 1 g calcium,
constant potassium (2.4 to 3.8 g, based on total caloric
requirement) and 80 g protein. On days 3 and 6, the
subjects received a single oral dose of either 100 mg
torsemide or 200 mg furosemide with sodium-free water
(10 mL/kg) to encourage diuresis. To ascertain sodium
balance, day 5 and day 6 body weights were desired to be
within 0.5 kg. Study drug was administered as either five
20 mg tablets of torsemide or five 40 mg tablets of furose-
mide, all encapsulated in opaque gelcaps to ensure blind-
ing from investigators, research staff, and subjects. So-
dium loss in the urine was not replaced with saline on
study days. However, on day 4, the subject received an
intravenous infusion of isotonic saline equivalent to the
amount of urinary sodium losses on day 3 to rapidly
reattain sodium balance. GFR was assessed on study
drug days by plasma clearance of an intravenous bolus
of iothalamate [12]. Measurements of urine electrolytes
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and protein were obtained at 0, 1, 2, 3, 4, 6, 9, 12, and
24 hours poststudy drug. During nonstudy drug inpatient
days, 24-hour urine specimens were collected daily in
day (6 a.m. to 10 p.m.) and night (10 p.m. to 6 a.m.)
aliquots. The subjects were discharged on day 7 and
instructed not to take any diuretic during the washout
phase.
Outpatient blood pressure efficacy study. Outpatient
trial design is illustrated in Figure 1B. After a 1-week
washout phase, subjects entered the blood pressure
study. The subjects were given a randomized, blinded,
fixed-dose, 3-week course of either 40 mg torsemide daily
in a single dose or 80 mg furosemide daily in two divided
doses. All subjects were prescribed two gelcaps twice
daily. Morning dose bottles and evening dose bottles
were packaged separately and marked accordingly. The
torsemide phase morning dose consisted of two gelcaps
containing 20 mg torsemide each, yielding a 40 mg dose,
with two placebo-containing gelcaps taken at the evening
dose. The furosemide phase morning and evening dose
both consisted of two gelcaps of 20 mg furosemide, yield-
ing 80 mg total daily dose. The 24-hour ambulatory blood
pressure measurements, serum and urine electrolytes
were measured at baseline, 1 week, and 3 weeks of ther-
apy. The subject then entered a 2-week washout period
followed by therapy with the second fixed-dose, blinded
drug with identical outcome measurements.
Subjects who experienced 40% increase in serum
creatinine from baseline to week 1 visit of the chronic
study had the diuretic dose halved or held at the discre-
tion of the investigator. The encapsulation of tablets in
bioequivalent half-dose increments allowed dose reduc-
tion without compromising study blinding. Subjects who
required half-dose of study drug consumed one gelcap
in the morning and one gelcap in the evening of allocated
study medication.
Laboratory analysis
Serum and urine electrolytes were measured by ion
selective electrodes; urine calcium was measured using
the Arsenazo III methodology [13] and urine creatinine
was measured using the Jaffe kinetic method [14]. Sam-
ples were assayed using the Cobas Mira analyzer (Roche
Diagnostics, Indianapolis, IN, USA). Urine protein was
measured by the dye-binding method using a complex
of pyrogallol red and molybdenum acid (QuanTtest Red
Total Protein Assay System, Quantimetrix, Redondo
Beach, CA, USA).
Plasma clearance of a 3 mL bolus of intravenous iothal-
amate meglumine (Conray 60, Mallinckrodt Medical,
Inc., St. Louis, MO, USA) was used to measure GFR.
Plasma samples were collected at 2, 3, 6, 9, and 12 hours
after the bolus and iothalamate measured by high-perfor-
mance liquid chromatography (HPLC) [12]. The product
of volume of distribution and elimination rate constant
of plasma iothalamate equaled the plasma clearance,
reflecting the GFR.
Ambulatory blood pressure measurements were re-
corded every 20 minutes during the day (6 a.m. to 10 p.m.)
and every 30 minutes during the night (10 p.m. to 6 a.m.)
using a Spacelabs 90207 ABP Monitor (SpaceLabs Medi-
cal, Inc., Redmond, WA, USA). Data were analyzed using
ABP Report Management System software, version 1.03.05
(SpaceLabs Medical Inc.). Subjects recorded awake and
asleep times in diaries that were used to calculate day-
time and nighttime blood pressure. Night to day systolic
blood pressure ratio of 0.9 defined the dipper status.
Blood pressure load was characterized by the percent of
readings above 135/85 mm Hg and percent of time that
readings exceeded this value.
Primary and secondary outcome measures
The primary outcome measure in the inpatient balance
study was a change in 24-hour urinary sodium excretion.
Secondary outcomes included potassium, calcium, and
protein excretion, diurnal variation of electrolyte and
protein excretion, and GFR. The primary outcome mea-
sure in the outpatient blood pressure efficacy study was
change in 24-hour ambulatory systolic blood pressure.
The data from subjects whose diuretics were held and
who were withdrawn from the study were utilized using
an intention-to-treat analysis.
Sample size and power analysis
Both phases were designed as an AB/BA crossover
trial. A two-sided paired t test was utilized to estimate
power. Based on prior urinary sodium excretion and
ambulatory systolic blood pressure data, we estimated a
standard deviation of the differences (pretreatment and
posttreatment) to be 55.8 mEq/day and 11.9 mm Hg,
respectively. Using a two-sided paired t test at the 5%
level of significance and assuming a correlation coeffi-
cient of 0.8 between the pretreatment and posttreatment
measurements, 14 subjects were required to provide 80%
power to detect a difference of 45 mEq sodium/day or
9.6 mm Hg systolic blood pressure between the diuretics.
Statistical analysis
The primary analyses of the inpatient and outpatient
phases involved detecting a difference in daily urinary
sodium excretion and ambulatory systolic blood pressure
between the two study medications, respectively. De-
scriptive statistics were calculated for the changes in so-
dium excretion and systolic blood pressure. Carryover
effects with respect to baseline sodium excretion and
systolic blood pressure were examined using the Wil-
coxon signed rank test and exact Wilcoxon rank sum
test. A linear mixed-effects model was used to assess
the carryover effect in the outcome variables. Since the
treatment differences between the changes in sodium
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Table 1. Baseline characteristics
Variable Total N  14 T/F N  7 F/T N  7 P value
Age years 6711 6812 6611 0.80a
Gender number (%) 1.00b
Male 13 (93) 6 (86) 7 (100)
Race number (%) 0.59b
Caucasian 8 (57) 3 (43) 5 (71)
African American 6 (43) 4 (57) 2 (29)
Weight kg 9625 8315 10828 0.06a
Body mass index kg/m2 338 295 368 0.10a
Systolic blood pressure mm Hg 15310 1548 15211 0.78a
Diastolic blood pressure mm Hg 815 806 815 0.82a
Heart rate beats/min 6910 6711 709 0.63a
Present tobacco use number (%) 3 (21) 2 (29) 1 (14) 1.00b
Antihypertensive medications number (%) 0.67c
1 3 (21) 0 (0) 3 (43)
2 3 (21) 3 (43) 0 (0)
3 2 (14) 1 (14) 1 (14)
4 4 (29) 2 (29) 2 (29)
4 2 (14) 1 (14) 1 (14)
Antihypertensive class
Diureticsd number (%) 6 (43) 2 (29) 4 (57) 0.59b
ACE inhibitors or ARBs number (%) 11 (79) 6 (86) 5 (71) 1.00b
-blockers number (%) 7 (50) 3 (43) 4 (57) 1.00b
Calcium channel blockers number (%) 5 (36) 3 (43) 2 (29) 1.00b
Previous myocardial infarction number (%) 1 (7) 1 (14) 0 (0) —
Previous stroke number (%) 0 (0) 0 (0) 0 (0) —
LVH by ECG number (%) 3 (21) 2 (29) 1 (14) 1.00b
Diabetes mellitus number (%) 8 (57) 4 (57) 4 (57) 1.00b
Hyperlipidemia number (%) 10 (71) 6 (86) 4 (57) 0.56b
Etiology of CKD number (%) 0.56b
Diabetes mellitus 3 (21) 2 (29) 1 (14)
Hypertension 10 (71) 4 (57) 6 (86)
Nephrectomy 1 (7) 1 (14) 0 (0)
Serum creatinine mg/dL 1.920.38 1.770.26 2.070.44 0.15a
MDRD GFR mL/min 4210 469 3911 0.25a
Proteinuria mg/day 12231759 12031034 12442374 0.97a
Sodium excretion mmol/day 18454 17865 19144 0.66a
Abbreviations are: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; LVH, left ventricular hypertrophy;
MDRD, modification in Diet in Renal Disease Study; GFR, glomerular filtration rate.
Baseline characteristics comparing subjects enrolled in the sequence where torsemide was given as the first study drug followed by furosemide as the second study
drug, T/F, with subjects given study drugs in reverse order, F/T.
a t test
b Fisher’s exact test
c Wilcoxon rank sum test, data are given as meanSD for continuous variables
d Diuretics were discontinued 1 month prior to study participation
excretion or systolic blood pressure did not closely follow
a normal distribution, the Wilcoxon signed rank test, a
nonparametric version of the paired t test was used to
compare the effects of torsemide and furosemide. Sub-
jects in two sequences were compared in terms of base-
line characteristics using t test for continuous variables
and Fisher exact test for dichotomous variables. Multi-
variate analysis of variance was used to analyze the out-
come variables at multiple time points. Analysis of covar-
iance was performed to ascertain the role of natriuresis
and diuretic treatment on ambulatory systolic blood pres-
sure lowering. Assumption of homogeneity of slopes was
tested by the F test. To assess agreement in natriuretic
response and systolic ambulatory blood pressure low-
ering, we calculated the limits of agreement as two times




Sixty subjects were screened for participation between
February 2001 and November 2001. Of these, 25 subjects
were ineligible because of failure to meet the inclusion
and exclusion criteria and 21 subjects declined participa-
tion. Fourteen subjects qualified and consented to partic-
ipate in the study. Actual subject study participation
occurred between March 2001 and January 2002. All
subjects completed the inpatient study. After a washout
period of 1 week, these 14 subjects received 3 weeks of
outpatient oral torsemide or furosemide. One subject
experienced prerenal azotemia and required discontinu-
ation of the study medication after 1 week of therapy.
After recovery to baseline, this subject was given half-
dose therapy, which again caused prerenal azotemia. The
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Fig. 2. Inpatient 24-hour urinary sodium excretions of torsemide (T)
and furosemide (F) for each subject. Symbols are: () subjects enrolled
in the sequence T/F; () subjects enrolled in the sequence F/T. Box
plots represents the median, 10th, 25th, 75th, and 90th percentiles of
each data set.
subject was withdrawn from the study with subsequent
resolution of renal failure. Thus, 13 subjects completed
the first phase of the outpatient study, and proceeded
to the 2-week washout period before crossing over to
the alternate treatment group. During this washout pe-
riod, one subject developed a respiratory tract infection,
received several doses of diuretics, and was withdrawn
from the study. Thus, 12 subjects entered the second
phase of the outpatient study. During the second phase,
one subject developed mild prerenal azotemia and hypo-
tension and was changed to half-dose therapy with reso-
lution of abnormalities. All 12 subjects completed the
second phase of the outpatient study.
Baseline demographic and clinical characteristics by
sequence are shown in Table 1. Subjects in each sequence
were similar with respect to demographic and clinical
characteristics. On average, study subjects were pre-
scribed three antihypertensive medications at baseline.
One subject admitted to taking occasional diuretics for
peripheral edema in the 1-month diuretic-washout phase
prior to trial commencement; despite the fact that this
technically represented a violation of eligibility criteria,
we presumed this self-treatment would not materially
affect response to treatment and therein included this
subject in the analysis.
Results for the inpatient sodium balance efficacy study
Data are presented as mean  SD. Baseline urinary
sodium excretions were similar before each sequence of
diuretic (P  0.66). There was no carryover effect with
respect to baseline urinary sodium excretions (P 0.54)
or response (P 0.25). As illustrated in Figure 2, a single
oral dose of torsemide caused a similar 24-hour urinary
sodium excretion as a twofold higher oral dose of furose-
mide, indicating this ratio of doses to be therapeutically
equivalent (P  0.67). Urinary sodium excretion in-
creased from baseline to posttreatment by 185  137
mEq/day for torsemide and 158 115 mEq/day for furo-
semide. Although torsemide increased sodium excretion
by 27  138 mEq/day more than furosemide, the differ-
ence was not statistically significant. Baseline body
weight was 94.7  26.7 kg before torsemide dosing and
94.5  26.7 kg before furosemide dosing (P  0.98). At
24 hours postdiuretic dosing, body weight was 93.3 
26.1 kg after torsemide and 93.6  26.4 kg after furose-
mide (P  0.97). There was no significant difference
between the two diuretics (P 0.99). Single-dose admin-
istration of loop diuretic acutely induced significant vol-
ume depletion characterized by 1.3% decrease in body
weight (P  0.001).
GFR measured by plasma iothalamate clearance aver-
aged 43  16 mL/min when torsemide was administered
and 47 18 mL/min when furosemide was administered.
There was no correlation between urinary sodium excre-
tion and GFR either with torsemide (r2  0.14, P  0.2)
or furosemide (r2 0.01, P  0.2).
Diurnal values for urinary sodium, potassium, calcium,
and protein to creatinine excretion data are shown in
Table 2. Sodium, potassium, and calcium excretion rates
were enhanced with both diuretics during the day and
led to compensatory retention at night. An acute reduc-
tion in protein excretion rate (normalized per gram creat-
inine excreted) also occurred with the administration of
both diuretics. For none of the above effects was there
a significant difference between the diuretics.
The time course of the diuretic response is shown in
Table 3. Electrolyte excretion rates were maximal during
the first 3 hours and showed diminishing excretion during
subsequent intervals. Again, there were no differences
in excretion rate profiles between the diuretics.
Results for the outpatient blood pressure
efficacy study
Baseline systolic blood pressures were similar with
both sequences (P 0.78). There was no carryover effect
with respect to baseline systolic blood pressure (P 
0.26). However, both torsemide and furosemide demon-
strated greater efficacy when administered in the sequence
furosemide-torsemide (F/T) than torsemidefurosemide
(T/F). This resulted in a significant interaction effect be-
tween treatment and period, indicating a significant car-
ryover effect during treatment. However, this carryover
effect was accounted for by considering the etiology of
CKD. As shown in Table 1, the distribution of CKD was
slightly dissimilar between the two groups. The sequence
T/F included a slightly higher number of subjects with
CKD secondary to diabetic nephropathy and nephrec-
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Table 2. Inpatient balance study
Torsemide (T) Furosemide (F)
Predose Postdose Response P valuea Predose Postdose Response with F P valuea T/F P valuea
Sodium mEq/interval 0.0001 0.0001 0.67
Day 13059 348123 217 (129, 305) 12033 32292 202 (125, 280) 15126
Night 8329 5136 32 (63, 1) 7927 3516 44 (64, 25) 1255
Total 21379 398142 185 (85, 285) 19949 35796 158 (74, 242) 27138
Potassium mEq/interval 0.001 0.001 0.97
Day 3713 5117 14 (6, 22) 3910 5412 15 (5, 24) 117
Night 176 136 4 (9, 1) 174 144 3 (7, 0) 010
Total 5418 6421 10 (0, 20) 5612 6715 11 (0, 22) 119
Calcium mg/interval 0.001 0.001 0.4
Day 4032 13364 93 (44, 142) 3731 10848 71 (38, 104) 2265
Night 1814 1813 0 (13, 14) 1817 1411 4 (15, 7) 526
Total 5842 15168 93 (42, 144) 5545 12256 67 (31, 102) 2769
Protein g/g creatinine/interval 0.029 0.17 0.17
Day 1.061.42 0.751.23 0.30 (0.64, 0.03) 0.951.48 0.691.12 0.260.45 0.040.57
Night 0.981.49 0.661.22 0.32 (0.68, 0.04) 0.941.30 0.892.28 0.051.49 0.271.62
Total 1.011.41 0.731.22 0.29 (0.54, 0.04) 0.931.39 0.741.43 0.200.41 0.090.39
Diurnal variation of analyte excretion during inpatient balance study.
a Denotes F test for multivariate analysis of variance. Day, 6 a.m. to 10 p.m. Night, 10 p.m. to 6 a.m. Data are presented as meanSD
Table 3. Inpatient balance study
Torsemide Furosemide T/F P value
Sodium mEq/hour 0.53
0 to 3 hours 45.817.9 47.313.9 1.523.5
3 to 6 hours 29.313.9 25.612.8 3.713.3
6 to 12 hours 14.39.6 11.56.9 2.89.4
12 to 22 hours 6.64.5 4.92.4 1.83.9
Potassium mEq/hour 0.95
0 to 3 hours 5.52.2 5.71.3 0.31.6
3 to 6 hours 3.71.6 4.01.5 0.31.7
6 to 12 hours 2.51.1 2.50.8 0.00.9
12 to 22 hours 1.80.7 1.70.4 0.10.6
Calcium mg/hour 0.19
0 to 3 hours 13.85.8 13.35.3 0.46.1
3 to 6 hours 11.99.7 10.57.9 1.412.5
6 to 12 hours 7.54.8 4.73.1 2.84.8
12 to 22 hours 3.11.7 1.81.3 1.31.6
Protein mg/hour 0.44
0 to 3 hours 50.483.2 60.5110.4 10.039.2
3 to 6 hours 29.550.3 35.895.6 6.357.1
6 to 12 hours 33.575.3 33.191.7 0.421.1
12 to 22 hours 40.797.0 45.7122.8 4.930.9
Time course of analyte excretion rates during inpatient balance study.
tomy than sequence F/T. Conversely, the sequence F/T
included a slightly higher number of subjects with CKD
secondary to hypertensive nephrosclerosis.
Figure 3A demonstrates that both treatments had sim-
ilar effects in reducing systolic blood pressure. There
was no statistical evidence of a treatment difference (P
0.43). The systolic blood pressure was reduced from
baseline to posttreatment by 9.7 10.0 mm Hg for torse-
mide (P  0.007) and 9.2  12.6 mm Hg for furosemide
(P  0.021).
Baseline body weight was 98.2 27.0 kg before outpa-
tient torsemide dosing and 99.2  27.5 kg before outpa-
tient furosemide dosing (P  0.94). After 3 weeks of
diuretic treatment, body weight was 98.4  26.7 kg after
torsemide and 98.0 27.0 kg after furosemide (P 0.98).
There was no significant difference in effect between the
two diuretics (P  0.81). Loop diuretic therapy did not
induce a significant change in body weight over 3 weeks
(P  0.32).
Treatment with either diuretic resulted in a decrease in
24-hour ambulatory systolic and diastolic blood pressure
(Table 4). Other parameters of blood pressure reduction
such as day and night blood pressure loads (percent of
readings above 135/85 mm Hg) were reduced as well.
Reductions in systolic blood pressure were more pro-
nounced than with diastolic blood pressure. Although
most subjects were nondippers (experienced a night to
day systolic systolic ratio of  0.9), neither diuretic had
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Fig. 3. Outpatient 24-hour ambulatory systolic (A) and diastolic (B)
blood pressure responses of chronic torsemide (T) and furosemide (F)
therapy for each subject. Symbols are: () subjects enrolled in the
sequence T/F; () subjects enrolled in the sequence F/T. Box plots
represents the median, 10th, 25th, 75th, and 90th percentiles of each
data set.
a significant effect on dipping status. Interestingly, torse-
mide resulted in a significantly greater elevation in heart
rate compared to furosemide. Reductions in blood pres-
sure were similar between torsemide and furosemide and
were not significantly different.
Relationship between acute diuretic response and
antihypertensive response
Both drugs produced comparable and significant re-
duction in blood pressure. This effect was related to the
natriuretic potency. For every 100 mEq of sodium excre-
tion with a single dose of diuretic, the reduction in systolic
blood pressure was 5.3 mm Hg (95% CI 1.9 mm Hg,
8.8 mm Hg). There was a steeper relationship between
sodium loss and systolic blood pressure reduction for
furosemide (11.1 mm Hg fall, 95% CI 3.0 to 14.9) than
Table 4. Ambulatory blood pressure study
Furosemide Torsemide
Predose Postdose Predose Postdose
SBP mm Hg 14717 13821 14318 13319
DBP mm Hg 7811 7412 7510 7110
HR beats/min 7210 7410 729 7711
Day SBP 14817 13922 14318 13418
Night SBP 14420 13522 14120 13021
Day DBP 7911 7512 769 7210
Night DBP 7312 7014 7112 6813
Day HR 7310 7511 6623 7224
Night HR 7010 7111 6722 6824
% load SBP 6933 5140 5938 4636
% time SBP 6834 5140 5938 4536
% load DBP 2427 1929 2128 1723
% time DBP 2427 2029 2028 1724
Dippers number 2 1 0 2
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; HR, heart rate. Comparison of ambulatory blood pressure hemodynamic
data between study drugs given for 3-week periods. Day readings are measured
by time awake and night readings are measured by time asleep.
torsemide (8.9 mm Hg fall, 95% CI 5.4 to 19.9); however,
the natriuretic blood pressure-lowering slopes were not
significantly different. Whereas the mean natriuretic re-
sponse between drugs was similar, the agreement between
torsemide and furosemide was moderate. The agreement
limit for natriuretic response was 275 mEq/day and the
intraclass correlation coefficient was 0.42. Similarly, the
agreement limits for systolic blood pressure lowering
was 21.5 mm Hg between the drugs with an intraclass
correlation coefficient of 0.56.
Safety and adverse events
The number of adverse events was similar in each
randomized group. One subject experienced severe pre-
renal azotemia requiring withdrawal from the trial. A
second subject developed mild prerenal azotemia that
resolved with decreasing the diuretic dose by half and
continued the trial without difficulty. A third subject
experienced dyspnea during the outpatient washout pe-
riod that responded to antibiotics and diuretics; this sub-
ject was withdrawn from the trial. A fourth subject devel-
oped an acute myocardial infarction during the last week
of the trial that was thought by the investigators to be
unrelated to diuretics, but rather related to the subject’s
underlying comorbidities. Cardiac intervention relieved
the symptoms and the subject finished the last week of
the trial. A fifth subject developed facial flushing and
nausea immediately after receiving an intravenous bolus
of iothalamate during the inpatient study. Symptoms
resolved within 15 minutes, and no further iothalamate
was administered to this subject throughout the trial.
DISCUSSION
The major findings of our study are (1) diuretic re-
sponse to bioequivalent doses of torsemide and furose-
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mide are similar; (2) antihypertensive response to bio-
equivalent doses of torsemide and furosemide in subjects
with CKD are also similar; and (3) antihypertensive re-
sponse is dependent on the natriuretic response.
Acute sodium balance study
Our trial demonstrated similar natriuretic, kaliuretic,
calciuretic, and blood pressure effects in subjects with
CKD between torsemide and furosemide when adminis-
tered in a randomized, blinded design. Consistent with
our results was a randomized, blinded, parallel group,
forced titration study that treated subjects with severe
CKD (baseline serum creatinine 6.5 mg/dL, not requiring
dialysis) with either 500 mg furosemide or 200 mg torse-
mide per day for 14 days, followed by double-dose di-
uretic for another 14 days [15]. No significant difference
between torsemide and furosemide with respect to blood
pressure, diuresis, natriuresis, calciuresis, or kaliuresis
occurred. Another double-blind parallel group trial in
subjects with severe CKD (mean creatinine clearance 9
to 12 mL/min) randomized subjects to three different
treatments after a run-in phase of 14 days with 500 mg
furosemide per day. The treatments were 100 mg torse-
mide, 200 mg torsemide, or 250 mg furosemide per day
each administered as a single daily dose for 14 days.
Urinary sodium excretions among the groups were
equivalent. Blood pressure also did not differ between
the groups [9].
Chronic blood pressure efficacy study
Both diuretics in our study induced a significant
change in both urinary sodium excretion and ambulatory
systolic blood pressure, reinforcing the utility of loop
diuretics in CKD for volume and blood pressure reduc-
tion. Although the mean blood pressure reduction in-
duced by the two diuretics was not statistically different,
the large standard deviations observed suggest that indi-
vidual blood pressure responses are unique and variable.
This observation suggests that individuals may exhibit
superior response to a specific diuretic and, therefore,
the substitution of one diuretic for the other may benefit
patients demonstrating diuretic tolerance.
Consideration of the pharmacokinetic properties of
furosemide led us to administer furosemide twice daily
for blood pressure reduction, rather than once daily.
Furosemide exhibits an elimination half-life of approxi-
mately 11⁄2 to 2 hours in healthy individuals and 3 hours
in CKD [7]. The urinary concentration of loop diuretic
determines the natriuretic effect [7]. Wilcox et al [16]
demonstrated that in healthy individuals, a daily intrave-
nous 40 mg dose of furosemide exerted natriuretic effect
over the first 6 hours after administration. However,
during the subsequent 18 hours, compensatory sodium
retention was noted, wherein urinary sodium excretion
was below baseline excretion rates, leading to an absence
of significant change in sodium balance from baseline.
Administration of an extremely low sodium diet (20 mEq/
day) could overcome this sodium retention and lead to
net negative sodium balance [16]. In clinical practice,
patients find it difficult to adhere to this degree of sodium
restriction chronically; the usage of twice daily furose-
mide administration avoids postdose sodium retention
and permits the development of negative sodium bal-
ance. It is likely that this negative sodium balance will
initiate blood pressure reduction. Therefore, the short
elimination half-life and postdose sodium retention sug-
gest that twice daily dosing would be of greater benefit,
although the question of once daily furosemide dosing
was not specifically addressed by our study.
There exist important limitations to this study. In com-
parison with many other hypertension trials, our study
had a small sample size. Thus, we may have insufficient
statistical power to detect differences in secondary out-
comes such as diurnal variation in response and impact
on proteinuria. Second, our subject population was pre-
dominantly male, as they were recruited from a VA medi-
cal center; however, we are unaware of literature support-
ing an interaction between diuretic response and gender.
In the clinical context, our study suggests that patients
with stages 2 and 3 CKD may derive similar blood pres-
sure reduction with furosemide, as with torsemide, which
may translate into significant cost benefits, though both
are now available generically. Alternatively, the finding
that a daily dosed treatment is therapeutically equivalent
to a twice daily dosed treatment may provide clinicians
the option of administering the more preferable once
daily dosing for blood pressure reduction. Both diuretics
induce excretion of electrolytes and possess the potential
to induce acute renal failure, and hence judicious use
and monitoring are essential to the safe use of this class
of blood pressure agent. This pharmacodynamic equiva-
lence of torsemide and furosemide does not hold true
for all edematous disease states. In subjects with hyper-
tension and edematous states such as congestive heart
failure and cirrhosis, a randomized, double-blind trial
found superior natriuresis, weight, and edema control
with both 10 and 20 mg of torsemide when compared
with 40 mg of furosemide [8, 17]. An open-label trial
comparing furosemide and torsemide in heart failure
revealed that subjects treated with torsemide required
fewer days of hospitalization for heart failure than those
treated with furosemide [18]. Indeed, there exists a com-
plicated and distinct interaction between the pharmaco-
kinetic properties of loop diuretics and the unique phar-
macodynamics in various disease states.
The ability of either diuretic to predominantly decrease
ambulatory systolic blood pressure may translate into sig-
nificant health benefits. Numerous randomized clinical
trials have established the strong association between
systolic blood pressure and cardiovascular disease [19–21].
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Additionally, pooling of the data available from random-
ized controlled clinical trials indicates that an average
reduction of 12 to 13 mm Hg in systolic pressure over 4
years of follow-up is associated with a 21% reduction
in coronary heart disease and 25% reduction in total
cardiovascular mortality rate [22]. In patients with CKD
who are already at high risk for cardiovascular morbidity,
loop diuretics may have a significant role in improving
these outcomes.
CONCLUSION
This study supports the administration of either furo-
semide or torsemide in subjects with CKD who require
antihypertensive therapy and does not find a difference
between the two loop diuretics with respect to efficacy
in subjects with stages 2 and 3 CKD.
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